Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

The path to clinical proteomics research: integration of proteomics, genomics, clinical laboratory and regulatory science.

Boja ES, Rodriguez H.

Korean J Lab Med. 2011 Apr;31(2):61-71. doi: 10.3343/kjlm.2011.31.2.61. Review.

2.

Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective.

Rodriguez H, Rivers R, Kinsinger C, Mesri M, Hiltke T, Rahbar A, Boja E.

Proteomics Clin Appl. 2010 Dec;4(12):904-14. doi: 10.1002/prca.201000057. Epub 2010 Nov 22. Review.

3.

Restructuring proteomics through verification.

Boja E, Rivers R, Kinsinger C, Mesri M, Hiltke T, Rahbar A, Rodriguez H.

Biomark Med. 2010 Dec;4(6):799-803. doi: 10.2217/bmm.10.92. Review.

4.

Analytical validation considerations of multiplex mass-spectrometry-based proteomic platforms for measuring protein biomarkers.

Boja ES, Fehniger TE, Baker MS, Marko-Varga G, Rodriguez H.

J Proteome Res. 2014 Dec 5;13(12):5325-32. doi: 10.1021/pr500753r. Epub 2014 Nov 18. Review.

5.

Label-free mass spectrometry-based proteomics for biomarker discovery and validation.

Pham TV, Piersma SR, Oudgenoeg G, Jimenez CR.

Expert Rev Mol Diagn. 2012 May;12(4):343-59. doi: 10.1586/erm.12.31. Review.

PMID:
22616700
6.

Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies.

Skates SJ, Gillette MA, LaBaer J, Carr SA, Anderson L, Liebler DC, Ransohoff D, Rifai N, Kondratovich M, Težak Ž, Mansfield E, Oberg AL, Wright I, Barnes G, Gail M, Mesri M, Kinsinger CR, Rodriguez H, Boja ES.

J Proteome Res. 2013 Dec 6;12(12):5383-94. doi: 10.1021/pr400132j. Epub 2013 Oct 28.

7.

Cancer proteomics.

Tan HT, Lee YH, Chung MC.

Mass Spectrom Rev. 2012 Sep-Oct;31(5):583-605. doi: 10.1002/mas.20356. Epub 2012 Mar 15. Review.

PMID:
22422534
8.

Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics.

Rodriguez H, Tezak Z, Mesri M, Carr SA, Liebler DC, Fisher SJ, Tempst P, Hiltke T, Kessler LG, Kinsinger CR, Philip R, Ransohoff DF, Skates SJ, Regnier FE, Anderson NL, Mansfield E; Workshop Participants.

Clin Chem. 2010 Feb;56(2):237-43. doi: 10.1373/clinchem.2009.136416. Epub 2009 Dec 10. Review.

9.

The molecular make-up of a tumour: proteomics in cancer research.

Kolch W, Mischak H, Pitt AR.

Clin Sci (Lond). 2005 May;108(5):369-83. Review.

PMID:
15831087
10.

The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.

Amacher DE.

Toxicol Appl Pharmacol. 2010 May 15;245(1):134-42. doi: 10.1016/j.taap.2010.02.011. Epub 2010 Feb 26. Review.

PMID:
20219512
11.

Computational biomarker pipeline from discovery to clinical implementation: plasma proteomic biomarkers for cardiac transplantation.

Cohen Freue GV, Meredith A, Smith D, Bergman A, Sasaki M, Lam KK, Hollander Z, Opushneva N, Takhar M, Lin D, Wilson-McManus J, Balshaw R, Keown PA, Borchers CH, McManus B, Ng RT, McMaster WR; Biomarkers in Transplantation and the NCE CECR Prevention of Organ Failure Centre of Excellence Teams.

PLoS Comput Biol. 2013 Apr;9(4):e1002963. doi: 10.1371/journal.pcbi.1002963. Epub 2013 Apr 4.

12.

Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.

Matta A, Ralhan R, DeSouza LV, Siu KW.

Mass Spectrom Rev. 2010 Nov-Dec;29(6):945-61. doi: 10.1002/mas.20296. Review.

PMID:
20945361
13.

Proteogenomic convergence for understanding cancer pathways and networks.

Boja ES, Rodriguez H.

Clin Proteomics. 2014 Jun 1;11(1):22. doi: 10.1186/1559-0275-11-22. eCollection 2014. Review.

14.

Regulatory perspective on translating proteomic biomarkers to clinical diagnostics.

Li J, Kelm KB, Tezak Z.

J Proteomics. 2011 Nov 18;74(12):2682-90. doi: 10.1016/j.jprot.2011.07.028. Epub 2011 Aug 11. Review.

PMID:
21856459
15.

Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration.

Regnier FE, Skates SJ, Mesri M, Rodriguez H, Tezak Z, Kondratovich MV, Alterman MA, Levin JD, Roscoe D, Reilly E, Callaghan J, Kelm K, Brown D, Philip R, Carr SA, Liebler DC, Fisher SJ, Tempst P, Hiltke T, Kessler LG, Kinsinger CR, Ransohoff DF, Mansfield E, Anderson NL.

Clin Chem. 2010 Feb;56(2):165-71. doi: 10.1373/clinchem.2009.140087. Epub 2009 Dec 10.

16.

Proteomics and islet research.

Ahmed M.

Adv Exp Med Biol. 2010;654:363-90. doi: 10.1007/978-90-481-3271-3_16. Review.

17.

The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients.

Kelleher MT, Fruhwirth G, Patel G, Ofo E, Festy F, Barber PR, Ameer-Beg SM, Vojnovic B, Gillett C, Coolen A, Kéri G, Ellis PA, Ng T.

Target Oncol. 2009 Sep;4(3):235-52. doi: 10.1007/s11523-009-0116-y. Epub 2009 Sep 16. Review.

18.

Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications.

de Wit M, Fijneman RJ, Verheul HM, Meijer GA, Jimenez CR.

Clin Biochem. 2013 Apr;46(6):466-79. doi: 10.1016/j.clinbiochem.2012.10.039. Epub 2012 Nov 13. Review.

PMID:
23159294
19.

Proteomics strategies for target identification and biomarker discovery in cancer.

Rajcevic U, Niclou SP, Jimenez CR.

Front Biosci (Landmark Ed). 2009 Jan 1;14:3292-303. Review.

PMID:
19273274
20.

Clinical proteomics for cancer biomarker discovery and therapeutic targeting.

Krieg RC, Paweletz CP, Liotta LA, Petricoin EF 3rd.

Technol Cancer Res Treat. 2002 Aug;1(4):263-72. Review.

PMID:
12625785
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk